ECSP15029808A - Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo - Google Patents
Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activoInfo
- Publication number
- ECSP15029808A ECSP15029808A ECIEPI201529808A ECPI201529808A ECSP15029808A EC SP15029808 A ECSP15029808 A EC SP15029808A EC IEPI201529808 A ECIEPI201529808 A EC IEPI201529808A EC PI201529808 A ECPI201529808 A EC PI201529808A EC SP15029808 A ECSP15029808 A EC SP15029808A
- Authority
- EC
- Ecuador
- Prior art keywords
- active ingredient
- tetrazole derivative
- solid dispersion
- enhanced solubility
- solubility including
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una dispersión sólida amorfa que comprende un derivado de tetrazol de la fórmula (I) o una sal farmacéuticamente aceptable del mismo como ingrediente activo. La dispersión sólida de la presente invención comprende un polímero hidrosoluble o un ácido con el fin de mejorar la solubilidad de su ingrediente activo, es decir, el derivado de tetrazol de la fórmula (I), mejorando de este modo su tasa de absorción y, por lo tanto, puede ser utilizado de manera eficaz para reducir la resistencia a múltiples fármacos (MDR) en las células cancerígenas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120145603A KR101986683B1 (ko) | 2012-12-13 | 2012-12-13 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15029808A true ECSP15029808A (es) | 2016-01-29 |
Family
ID=50934681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201529808A ECSP15029808A (es) | 2012-12-13 | 2015-07-11 | Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US9283218B2 (es) |
| EP (1) | EP2931720B1 (es) |
| JP (1) | JP6355645B2 (es) |
| KR (1) | KR101986683B1 (es) |
| CN (1) | CN104870443B (es) |
| AR (2) | AR093706A1 (es) |
| AU (1) | AU2013360544B2 (es) |
| BR (1) | BR112015013905A2 (es) |
| CA (1) | CA2892376C (es) |
| CL (1) | CL2015001551A1 (es) |
| CR (1) | CR20150361A (es) |
| DK (1) | DK2931720T3 (es) |
| DO (1) | DOP2015000128A (es) |
| EC (1) | ECSP15029808A (es) |
| ES (1) | ES2731806T3 (es) |
| GT (1) | GT201500123A (es) |
| HU (1) | HUE044659T2 (es) |
| IL (1) | IL239327A (es) |
| JO (1) | JO3534B1 (es) |
| LT (1) | LT2931720T (es) |
| MX (1) | MX363644B (es) |
| MY (1) | MY174746A (es) |
| NI (1) | NI201500073A (es) |
| NZ (1) | NZ709071A (es) |
| PE (1) | PE20151066A1 (es) |
| PH (1) | PH12015501312B1 (es) |
| PL (1) | PL2931720T3 (es) |
| PT (1) | PT2931720T (es) |
| PY (1) | PY1358434A (es) |
| RU (1) | RU2662819C2 (es) |
| SA (1) | SA515360535B1 (es) |
| SG (1) | SG11201504067SA (es) |
| SI (1) | SI2931720T1 (es) |
| TR (1) | TR201908746T4 (es) |
| TW (1) | TWI652073B (es) |
| UY (1) | UY35186A (es) |
| WO (1) | WO2014092489A1 (es) |
| ZA (1) | ZA201503795B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102044223B1 (ko) * | 2016-09-12 | 2019-11-13 | 성균관대학교산학협력단 | 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법 |
| JP7561629B2 (ja) | 2018-03-07 | 2024-10-04 | シアン チェン アンドリュー | 不溶性薬物用の水性製剤 |
| CZ2018188A3 (cs) * | 2018-04-18 | 2019-10-30 | Zentiva, K.S. | Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek |
| AU2019395284B2 (en) * | 2018-12-14 | 2025-07-17 | Health Hope Pharma Hk Limited | Therapeutic combinations of orally administered irinotecan and a P-gp inhibitor for the treatment of cancer |
| EP3893867A1 (en) | 2018-12-14 | 2021-10-20 | Athenex HK Innovative Limited | Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer |
| US12404267B2 (en) * | 2019-02-14 | 2025-09-02 | Assia Chemical Industries Ltd. | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt |
| US20230278990A1 (en) * | 2020-07-10 | 2023-09-07 | Teva Czech Industries S.R.O | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt |
| JP7823036B2 (ja) | 2020-10-07 | 2026-03-03 | ヘルス ホープ ファーマ エイチケー リミテッド | アセトアミド－フェニルテトラゾール誘導体およびその使用方法 |
| JP2023548384A (ja) * | 2020-10-30 | 2023-11-16 | アテネックス アールアンドディ エルエルシー | Ｈｍ３０１８１メシル酸塩の多形 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| JP2000309588A (ja) * | 1999-04-28 | 2000-11-07 | Taisho Pharmaceut Co Ltd | 固体分散体 |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| CA2534371A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| KR100557093B1 (ko) * | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| KR100572411B1 (ko) | 2003-10-23 | 2006-04-18 | 한미약품 주식회사 | 열역학적으로 안정한 무정형 토라세미드 고체분산체와이를 포함하는 약학 조성물 및 이의 제조 방법 |
| WO2006046623A1 (ja) * | 2004-10-25 | 2006-05-04 | Japan Tobacco Inc. | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
| KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
| ZA200801893B (en) * | 2005-08-29 | 2009-08-26 | Sanofi Aventis Us Llc | Amorphous solid dispersions of 7-chloro-N,N, 5-Trimethyl-4-Oxo-3-phenyl-3, 5,-dihydro-4H-pyridazino [4,5-B] indole-1-acetamide |
| KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
| KR20110132116A (ko) * | 2010-06-01 | 2011-12-07 | (주)국전약품 | 라록시펜 염산염을 포함하는 고체분산체, 이의 제조방법, 및 이를 포함하는 경구용 제제 |
| BR112012031516A2 (pt) * | 2010-06-09 | 2016-11-08 | Abbott Lab | dispersões sólidas contendo inibidores de quinase |
-
2012
- 2012-12-13 KR KR1020120145603A patent/KR101986683B1/ko active Active
-
2013
- 2013-12-03 AR ARP130104460A patent/AR093706A1/es not_active Application Discontinuation
- 2013-12-06 PY PY201301358434A patent/PY1358434A/es unknown
- 2013-12-11 JO JOP/2013/0361A patent/JO3534B1/ar active
- 2013-12-12 TR TR2019/08746T patent/TR201908746T4/tr unknown
- 2013-12-12 CN CN201380064980.5A patent/CN104870443B/zh active Active
- 2013-12-12 NZ NZ709071A patent/NZ709071A/en unknown
- 2013-12-12 EP EP13863463.9A patent/EP2931720B1/en active Active
- 2013-12-12 PL PL13863463T patent/PL2931720T3/pl unknown
- 2013-12-12 PE PE2015000908A patent/PE20151066A1/es unknown
- 2013-12-12 UY UY0001035186A patent/UY35186A/es active IP Right Grant
- 2013-12-12 ES ES13863463T patent/ES2731806T3/es active Active
- 2013-12-12 BR BR112015013905A patent/BR112015013905A2/pt not_active Application Discontinuation
- 2013-12-12 SG SG11201504067SA patent/SG11201504067SA/en unknown
- 2013-12-12 JP JP2015547856A patent/JP6355645B2/ja active Active
- 2013-12-12 WO PCT/KR2013/011545 patent/WO2014092489A1/en not_active Ceased
- 2013-12-12 SI SI201331462T patent/SI2931720T1/sl unknown
- 2013-12-12 CA CA2892376A patent/CA2892376C/en active Active
- 2013-12-12 MX MX2015006416A patent/MX363644B/es unknown
- 2013-12-12 US US14/439,735 patent/US9283218B2/en active Active
- 2013-12-12 MY MYPI2015701648A patent/MY174746A/en unknown
- 2013-12-12 RU RU2015128002A patent/RU2662819C2/ru active
- 2013-12-12 TW TW102145931A patent/TWI652073B/zh active
- 2013-12-12 LT LTEP13863463.9T patent/LT2931720T/lt unknown
- 2013-12-12 PT PT13863463T patent/PT2931720T/pt unknown
- 2013-12-12 DK DK13863463.9T patent/DK2931720T3/da active
- 2013-12-12 HU HUE13863463 patent/HUE044659T2/hu unknown
- 2013-12-12 AU AU2013360544A patent/AU2013360544B2/en active Active
-
2015
- 2015-05-25 GT GT201500123A patent/GT201500123A/es unknown
- 2015-05-26 NI NI201500073A patent/NI201500073A/es unknown
- 2015-05-27 ZA ZA2015/03795A patent/ZA201503795B/en unknown
- 2015-05-29 DO DO2015000128A patent/DOP2015000128A/es unknown
- 2015-06-05 CL CL2015001551A patent/CL2015001551A1/es unknown
- 2015-06-06 SA SA515360535A patent/SA515360535B1/ar unknown
- 2015-06-09 PH PH12015501312A patent/PH12015501312B1/en unknown
- 2015-06-10 IL IL239327A patent/IL239327A/en active IP Right Grant
- 2015-07-09 CR CR20150361A patent/CR20150361A/es unknown
- 2015-07-11 EC ECIEPI201529808A patent/ECSP15029808A/es unknown
-
2021
- 2021-10-13 AR ARP210102833A patent/AR123783A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15029808A (es) | Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo | |
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| BR112014027601A2 (pt) | picolinamidas macrocíclicas como fungicidas | |
| AR122463A2 (es) | Suspensiones de nanopartículas que contienen polímero de carboxivinilo | |
| NZ721175A (en) | Syk inhibitors | |
| CO6680717A2 (es) | Derivados de quinolina y quinoxalina como inhibidores de cinasa | |
| EA201490919A1 (ru) | Производные бетулина | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| CL2012003488A1 (es) | Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias. | |
| IN2012DE00497A (es) | ||
| WO2014182789A3 (en) | Radiomitigating pharmaceutical formulations | |
| UY35323A (es) | Derivados sustituidos del ácido bisfenil butanóico como inhibidores de la nep con una mejorada efic acia in vivo | |
| CR20160116A (es) | Método para tratar onicomicosis con hidroxipropil quitasano | |
| AR130558A2 (es) | Composición farmacéutica que comprende ledipasvir y sofosbuvir, forma de dosificación farmacéutica y comprimido que la comprenden | |
| EP3031462A4 (en) | Medicine for preventing or suppressing survival of cancer cells and having organic acid polymer as active ingredient | |
| AR095131A1 (es) | Formulación combinada de dos compuestos antivirales | |
| UA103450C2 (ru) | Фолат-конъюгированный ферроцен как биологически активное соединение медицинского назначения |